Advertisement
Screener

GEOVAX LABS, INC. (GOVX) Retained Earnings

2.8 / 5 stars · 68/120 Roast Me

GEOVAX LABS, INC. Retained Earnings

GEOVAX LABS, INC. (GOVX) had Retained Earnings of -$160.51 million as of 2026-06-30, per its S-1 filed 2026-09-17.

Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent

us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-09-17

  • 2026-06-30: Retained Earnings (Accumulated Deficit) -$160.51M.
  • 2026-03-31: Retained Earnings (Accumulated Deficit) -$156.08M.
  • 2025-12-31: Retained Earnings (Accumulated Deficit) -$150.82M.
  • 2025-09-30: Retained Earnings (Accumulated Deficit) -$146.40M.
Period endRetained Earnings (Accumulated Deficit)
2026-06-30-$160.51M
S-1 · filed 2026-09-17
2026-03-31-$156.08M
10-Q · filed 2026-05-14
2025-12-31-$150.82M
S-1 · filed 2026-09-17
2025-09-30-$146.40M
10-Q · filed 2025-11-13
2025-06-30-$140.08M
10-Q · filed 2025-07-28
2025-03-31-$134.71M
10-Q · filed 2025-05-01
2024-12-31-$129.36M
S-1 · filed 2026-09-17
2024-09-30-$121.09M
10-Q · filed 2024-11-12
2024-06-30-$115.28M
10-Q · filed 2024-08-06
2024-03-31-$110.21M
10-Q · filed 2024-05-14
2023-12-31-$104.36M
10-K · filed 2025-03-27
2023-09-30-$96.77M
10-Q · filed 2023-11-08
2023-06-30-$88.36M
10-Q · filed 2023-08-09
2023-03-31-$82.43M
10-Q · filed 2023-05-04
2022-12-31-$78.40M
10-K · filed 2024-02-29
2022-09-30-$73.01M
10-Q · filed 2022-11-09
2022-06-30-$69.05M
10-Q · filed 2022-08-03
2022-03-31-$66.80M
10-Q · filed 2022-04-27
2021-12-31-$64.38M
10-K · filed 2023-03-23
2021-09-30-$50.63M
10-Q · filed 2021-11-12
2021-06-30-$48.68M
10-Q · filed 2021-08-11
2021-03-31-$47.37M
10-Q · filed 2021-05-06
2020-12-31-$45.81M
10-K · filed 2022-03-09
2020-09-30-$44.47M
10-Q · filed 2020-11-05
2020-06-30-$43.90M
10-Q · filed 2020-08-10
2020-03-31-$43.44M
10-Q · filed 2020-05-05
2019-12-31-$42.85M
10-K · filed 2021-03-23
2019-09-30-$42.26M
10-Q · filed 2019-11-07
2019-06-30-$41.83M
10-Q · filed 2019-08-13
2019-03-31-$41.18M
10-Q · filed 2019-05-13
2018-12-31-$40.48M
10-K · filed 2020-03-24
2018-09-30-$39.84M
10-Q · filed 2018-11-08
2018-06-30-$39.18M
10-Q · filed 2018-08-07
2018-03-31-$38.54M
10-Q · filed 2018-05-03
2017-12-31-$37.92M
10-K · filed 2019-03-26
2017-09-30-$37.40M
10-Q · filed 2017-11-09
2017-06-30-$36.81M
10-Q · filed 2017-08-14
2017-03-31-$36.29M
10-Q · filed 2017-05-12
2016-12-31-$35.75M
10-K · filed 2018-03-23
2016-09-30-$34.81M
10-Q · filed 2016-11-14
2016-06-30-$34.35M
10-Q · filed 2016-08-05
2016-03-31-$33.77M
10-Q · filed 2016-05-04
2015-12-31-$32.47M
10-K · filed 2017-03-24
2015-09-30-$31.78M
10-Q · filed 2015-11-12
2015-06-30-$31.16M
10-Q · filed 2015-08-04
2014-12-31-$29.79M
10-K · filed 2016-03-16

Similar stocks

Stock NameCountryMarket CapPE Ratio
Petros Pharmaceuticals, Inc. (PTPI)United States$0.003B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
Genprex, Inc. (GNPX)United States$0.003B-0.02
Alaunos Therapeutics, Inc. (TCRT)United States$0.003B-1.44
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
Sunshine Biopharma Inc. (SBFM)$0.003B
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
ORAGENICS INC (OGEN)United States$0.002B